garner joined Kazia back in 2015-16 from middle management in big Pharma. He came in to a co with $44 mil in cash. He bought in a 'Phase 2 ready clinical asset'. Which he then spent money re-running a P1 study, early demonstration of incompetence and communication strategy.
He then proceeded to open multiple trials and blow thru the $ at an amazing rate. If you look at his ability to meet clinical trial readout milestones, that HE PUBLISHED he has a 100% failure rate. His ability to raise capital is just about nonexistent. His inability to reach milestones translated to no one in the VC world trusting him with their investment dollars. This meant he opened up an At The Market (ATM) facility that he rolled out over 18 months that diluted at an unbelievable rate. It got to the stage that his inability to finish studies on time and only raise $ thru a questionable ATM facility saw him stripped of his option package and shown the door.
Antisense have someone that has had formal ASIC investigations thru his mismanagement of corporate announcements (ask for it under FOI, the board should have picked up on this!).Kazia stock was manipulated during his tenure, due to his inability to meet his own deadlines and opened it to endless short selling cycles.
Antisrnse wasn't on my radar until he joined, apologies but it is now, just to make $ off the short cycles that will become a regular part of Antisense's future, until the board wakes up and boots him!
Look at his history, he is not a turn around CEO, he is future chapters in MBA courses on what not to do in Biotech ....
ANP Price at posting:
5.3¢ Sentiment: Sell Disclosure: Not Held
